Zenas BioPharma is a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world. The company has a deep pipeline of innovative autoimmune therapeutics and is rapidly advancing seven pipeline programs, including three with worldwide rights. Zenas aims to transform the lives of patients living with autoimmune diseases.

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies for patients around the world. Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com.

Longitude Capital

Superstring Capital

Tellus BioVentures

Fairmount Funds Management

Perceptive Advisors

Pivotal bioVenture Partners

Quan Capital

Vivo Capital

Wellington Management

Xencor

Zenas BioPharma

The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the NASDAQ Biotechnology IndexÂ®.
 The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund&#39;s investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

ProShares UltraPro Short Nasdaq Biotechnology

ZBIO

COM:ZENASBIO

Zenas BioPharma

Last Close

10.44

22/11 21:00

Market Cap

2.50M

Beta: -

Volume Today

785.07K

Avg: -

Analysis Not Available